Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Rating of “Moderate Buy” by Brokerages

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has received an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $15.80.

Several brokerages have issued reports on AMRX. Weiss Ratings cut Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. UBS Group began coverage on Amneal Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $19.00 price objective on the stock. Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Barclays upped their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Finally, Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday.

Amneal Pharmaceuticals Stock Up 3.7%

Shares of NASDAQ AMRX opened at $17.27 on Thursday. The stock’s 50 day moving average price is $13.65 and its two-hundred day moving average price is $13.33. Amneal Pharmaceuticals has a 52-week low of $7.66 and a 52-week high of $17.40. The stock has a market capitalization of $5.51 billion, a P/E ratio of 45.45 and a beta of 1.30.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The firm had revenue of $722.52 million for the quarter. On average, analysts anticipate that Amneal Pharmaceuticals will post 0.92 EPS for the current year.

Insider Transactions at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the sale, the director directly owned 93,660 shares in the company, valued at approximately $1,211,960.40. This represents a 27.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 17.30% of the stock is owned by insiders.

Institutional Trading of Amneal Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in AMRX. Kemnay Advisory Services Inc. acquired a new stake in shares of Amneal Pharmaceuticals during the 4th quarter worth approximately $26,000. Federated Hermes Inc. raised its position in shares of Amneal Pharmaceuticals by 1,680.6% during the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares during the period. Comerica Bank raised its position in shares of Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares during the period. Spire Wealth Management raised its position in shares of Amneal Pharmaceuticals by 66.6% during the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after purchasing an additional 1,023 shares during the period. Finally, Transamerica Financial Advisors LLC raised its position in shares of Amneal Pharmaceuticals by 541.9% during the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after purchasing an additional 2,460 shares during the period. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.